Antitumor activity of titanocene dichloride in xenografted human renal-cell carcinoma

Anticancer Research

Volumn 19, Issue 1 A, 1999, Pages 493-504

  Kopf Maier P ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Antitumor activity; Human renal cell carcinoma; In vivo and in vitro experiments; Metallocene; Titanocene dichloride

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; FLOXURIDINE; FLUOROURACIL; MKT 5; TITANOCENE DICHLORIDE; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL GROWTH; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FORMULATION; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY CARCINOMA; MONOLAYER CULTURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; KIDNEY NEOPLASMS; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; ORGANOMETALLIC COMPOUNDS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0344938002     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Köpf H, Köpf-Maier P: Titanocen-dichlorid - das erste Metallocen mit cancerostatischer Wirksamkeit. Angew Chem 91: 509-510: Angew Chem Int Ed Engl 18: 477, 1979.
2. Köpf H, Köpf-Maier P: Titanocen-dichlorid - das erste Metallocen mit cancerostatischer Wirksamkeit. Angew Chem 91: 509-510: Angew Chem Int Ed Engl 18: 477, 1979.
3. Köpf-Maier P, Köpf H: Tumor inhibition by titanocene complexes. Activity against B16 melanoma and colon 38 carcinoma. Arzneim Forsch / Drug Res 37: 532-534, 1987.
4. Köpf-Maier P. Köpf H: Transition and main-group metal cyclopentadienyl complexes: preclinical studies on a series of antitumor agents of different structural type. Struct Bond 70: 103-185, 1988.
5. Köpf-Maier P: Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract. Cancer Chemother Pharmacol 23: 225-230, 1989.
6. Köpf-Maier P: Antitumor bis(cyclopentadienyl)metal complexes. In: Metal Complexes in Cancer Chemotherapy (ed Keppler BK), VCH Verlagsgesellschaft mbH, Weinheim, 259-296, 1993.
7. Köpf-Maier P, Köpf H: Organometallic titanium, vanadium, niobium, molybdenum and rhenium complexes early transition metal antitumour drugs. In: Metal Compounds in Cancer Therapy (ed Fricker SP) Chapman and Hall, London, 109-146, 1994.
8. Cao S, Durrani FA, Baumgart J, Sass G, Rustum YM: Titanocene dichloride a new organometallic compound, active in vivo against varieties of human tumors with differential sensitivity to doxorubicin and cisplatin. Proc Amer Assoc Cancer Res Ann Meet, Toronto/,Canada, March 18-22, 1995, Abstract No 2330 , 1995.
9. Berdel WE, Schmoll HJ, Scheulen ME, Korfel A, Gründel O, Harstrick A, Knoche M, Fels LM, Bach F, Baumgart J, Sass G: Phase I clinical and pharmacokinetic study of titanocene dichloride in advanced solid tumors. Proc Amer Soc Clin Oncol, Los Angeles, May 20-23, 1995, Abstract No 1512, 1995.
10. Korfel A, Schmoll HJ, Scheulen ME, Knoche MF, Harstrick A, Bach F, Baumgart J, Sass G, Thiel E, Berdel WE: Klinische Phase-I-Studie mit Titanocendichlorid bei Patienten mit soliden Tumoren. Akt Onkol 84: 51-59, 1995.
11. Köpf-Maier P: 1996. The organ toxicity of the antitumor agent titanocene dichloride is dependent on the route and schedule of application. Ann Oncol 7 (Suppl 1) Abstract No 402, 1996.
12. Bastert GB, Fortmeyer HP, Schmidt-Matthiesen H: Thymus Aplastic Nude Mice and Rats in Clinical Oncology. Gustav Fischer Verlag, Stuttgart, New York, 1981.
13. Fiebig HH, Löhr GW: 1984. Wachstum menschlicher Malignome und Entwicklung von Tumormodellen in der thymusaplastischen Nacktmaus. Beitr Onkol 18: 287-314, 1984.
14. Fiebig HH, Berger DP (eds): Immunodeficient Mice in Oncology. Karger, Basel, München, 1992.
15. Arnold W, Köpf-Maier P, Michael B (eds): Immunodeficient Animals: Models for Cancer Research. Karger, Basel, Freiburg, 1996.
16. Scheulen ME, Harstrick A, Korfel A, Knoche M, Kading J, Skorzec M. Baumgart J, Seeber S: Untersuchung der Pharmakokinetik von intravenös verabreichtem Titanocendichlorid (Titanocen) im Rahmen einer klinischen Phase-I-Studie. Akt Onkol 84: 37-50, 1995.
17. Vendrig DE, Teeuwsen J, Holthuis JJ: Analysis of vinca alkaloids in plasma and urine using high-performance liquid chromatography with electrochemical detection. J Chromatogr 424: 83-94, 1988.
18. Chong CD, Logothetis CJ, Savaraj N, Fritsche HA, Gietner AM, Samuels ML: The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. J Clin Pharmacol 28: 714-718, 1988.
19. Muggia FM, Chan KK, Russell C, Colombo N, Speyer JL, Sehgal K, Jeffers S, Sorich J, Leichman L, Beller U: Phase I and pharmacologic evaluation of intraperitoneal 5-fluoro-2'-deoxyuridine. Cancer Chemother Pharmacol 28: 241-250, 1991.
20. Laar van JAM, Durrani FA, Mane R, Rustum YM: In vivo modulation of the therapeutic efficacy of floxuridine (FUdr) by PALA. Proc Am Assoc Cancer Res 33: 422 (abstract No 2519), 1992.
21. Kühböck J: Survey of chemotherapy of metastatic renal cancer. Sem Surg Oncol: 87-90, 1988.
22. Damascelli B, Marchianò A, Spreafico C, Lutman R, Salvetti M, Bonalumi MG, Mauri M, Garbagnati F, Del Nero A, Comeri G, Conti G, Copoli S, Benetti G, Tralongo P, Belussi D: Circadian continuous chemotherapy of renal cell carcinoma with an implantable, programmable infusion pump. Cancer 66: 237-241, 1990.
23. Hrushesky WJM, von Roemeling R, Lanning RM, Rabatin JT: Circadian-shaped infusion of floxuridine for progressive metastatic renal cell carcinoma. J Clin Oncol 8: 1504-1513, 1990.
24. Meadows LM, Walther P, Ozer H: α-Interferon and 5-fluorouracil: possible mechanisms of antitumor action. Sem Oncol 18: 71-76, 1991.
25. Dexeus FH, Logothetis CJ, Sella A, Amato R, Kilbourn R, Ogden S, Striegel A, Kwan J, Newman RA: Circadian infusion of floxuridine in patients with metastatic renal cell carcinoma. J Urol 146: 709-713, 1991.
26. Fossa SD, Droz JP, Pavone-Macaluso MM, Debruyne FJJ, Vermeylen K, Sylvester R: Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. Eur J Cancer 28A: 878-880, 1992.
27. Huben RP: Advances in chemotherapy for renal cell carcinoma. Sem Urol X: 16-22, 1992.
28. Choudhury M, Efros M, Mittelman A: Interferons and interleukins in metastatic renal cell carcinoma. Suppl Urol 41:67-72, 1993.
29. 2b. World J Urol 9: 223-227, 1991.
30. 2b. Int J Oncol 6: 947-954, 1995.
31. Kurbacher CM, Nagel W, Mallmann P, Kurbacher JA, Sass G, Hübner H, Andreotti PE, Krebs D: In vitro activity of titanocene dichloride in human renal cell carcinoma compared to conventional antineoplastic agents. Anticancer Res 14: 1529-1534, 1994.
32. Köpf-Maier P, Wagner W, Köpf H: In vitro cell growth inhibition by metallocene dichlorides. Cancer Chemother Pharmacol 5: 237-241, 1981.
33. Köpf-Maier P, Hermann G: Cytologic observations on the effects of metallocene dichlorides on human fibroblasts cultivated in vitro. Virchows Arch [Cell Pathol] 47: 107-122, 1984.
34. Christodoulou C, Eliopoulos A, Young LS, Ferry DR, Hodgkins L, Kerr DJ: Titanocene dichloride, a novel metal-complex compound, exhibits cytotoxic activity in vitro. Proc Amer Assoc Cancer Res Ann Meet, Washington, April 20-24, 1996, Abstract No 2680, 1996.
35. Matsuoka H, Sugimachi K, Yano K: Chemosensitivity testing for anticancer drugs using confluent monolayers. Med Sci Res 15: 837-838, 1987.
36. Scheithauer W, Clark GM, Moyer MP, Von Hoff DD: New screening system for selection of anticancer drugs for treatment of human colorectal cancer. Cancer Res 46: 2703-2708, 1986.
37. Kao JWY, Collins JL: A rapid in vitro screening system for the identification and evaluation of anticancer drugs. Cancer Invest 7: 303-311, 1989.
38. Smit EF, De Vries EGE, Timmer-Bosscha H, De Leij LFHM, Oosterhuis JW, Scheper RJ, Weening JJ, Postmus PE, Mulder NH: In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs: no correlation with clinical data. Int J Cancer 51: 72-78, 1992.
39. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461-463 , 1977.
40. Lieber MM: Soft agar colony formation assay for in vitro chemotherapy sensitivity testing of human renal cell carcinoma: Mayo Clinic experience. J Urol 131: 391-393, 1984.
41. Hashimura Y, Tanigawa N, Okada K, Yoshida O: Clonogenic assay for urologie malignancies. Gann 75: 724-728, 1984.
42. Bulbul MA, Pavelic K, Slocum HK, Frankfurt OS, Rustum YM, Huben RP, Bernacki RJ: Growth of human urologie tumors on extracellular matrix. J Urol 136: 512-516, 1986.
43. Freeman AE, Hoffman RM: In vivo-like growth of human tumors in vitro. Proc Natl Acad Sci USA 83: 2694-2698, 1986.
44. Uchibayashi T, Egawa M, Hisazumi H, Hasegawa T, Tanaka T, Sasaki T: In vitro chemosensitivity test for human genitourinary tumors using collagen gel matrix. Eur Urol 24: 267-270, 1993.
45. Köpf-Maier P, Kolon B: An organoid culture assay (OCA) for determining the drug sensitivity of human tumors. Int J Cancer 51: 99-107, 1992.
46. Köpf-Maier P, Kolon B, Bugenings M: Morphological and functional reorganization of human carcinomas in vitro. Int Rev Cytol 155: 181-257, 1994.
47. Miller BE, Miller FR, Heppner GH: Factors affecting growth and drug sensitivity of mouse mammary tumor lines in collagen gel cultures. Cancer Res 45: 4200-4205, 1985.